Overview
Human Growth Hormone (HGH), pharmaceutically known as Somatropin, is a recombinant form of the 191-amino-acid single-chain polypeptide hormone naturally produced and secreted by somatotroph cells of the anterior pituitary gland. Recombinant somatropin is manufactured using recombinant DNA technology and is structurally identical to endogenous human growth hormone.
Important distinction — approved medicine vs. off-label use: Somatropin is a well-established, EMA- and HPRA-recognised approved medicine with an extensive body of real clinical trial literature. It is approved for specific medical indications including paediatric growth hormone deficiency, Turner syndrome, chronic renal insufficiency-related growth failure, Prader-Willi syndrome, small for gestational age (SGA) children who fail to catch up in growth, and adult growth hormone deficiency (AGHD), among other indications depending on jurisdiction and specific product licence. Separately, HGH also has significant off-label use in anti-ageing and bodybuilding/performance-enhancement contexts — this use is
not an approved indication anywhere, is not supported by the same level or type of controlled trial evidence as the approved indications, and carries a different risk-benefit profile. This guide addresses both contexts and keeps them clearly distinguished throughout. This guide is for educational and research purposes only. Not medical advice.
Clinical & Research Status
| Evidence Type |
Status |
| Human RCT |
✔ (extensive, for approved indications) |
| Observational |
✔ |
| Animal Studies |
✔ |
| In Vitro |
✔ |
| Regulatory Approval |
✔ for specific medical indications (EMA/HPRA-approved products); ✗ for anti-ageing, cosmetic or bodybuilding/performance use (not an approved indication in any jurisdiction) |
Mechanism of Action
Growth hormone acts through two principal mechanisms: a direct pathway, where GH binds directly to growth hormone receptors (GHR) on target tissues including liver, muscle, bone and adipose tissue, activating the JAK2-STAT5 signalling cascade; and an indirect pathway, where GH stimulates hepatic (and some local tissue) production of insulin-like growth factor 1 (IGF-1), which mediates many of GH's anabolic and growth-promoting effects, particularly linear bone growth during childhood via epiphyseal plate chondrocyte proliferation.
Physiologically, GH has both anabolic and lipolytic (fat-mobilising) actions: it promotes protein synthesis and nitrogen retention, stimulates lipolysis in adipose tissue (making fat available as an energy substrate), and has a counter-regulatory, mildly diabetogenic effect on glucose metabolism by reducing peripheral insulin sensitivity — a mechanism relevant to monitoring during both approved clinical use and any off-label use context. In children, sustained GH/IGF-1 signalling drives linear growth; in adults, GH deficiency is associated with altered body composition (increased fat mass, reduced lean mass), reduced bone mineral density and adverse lipid profiles, which is the physiological basis for adult GH deficiency replacement therapy.
Research Areas & Reported Effects
Paediatric Growth Hormone Deficiency and Growth Disorders (Approved Indication)
The largest and most robust body of somatropin clinical trial literature covers paediatric use for growth hormone deficiency, Turner syndrome, Prader-Willi syndrome, chronic kidney disease-related growth failure and small-for-gestational-age children. Decades of RCT data demonstrate improved height velocity and adult height outcomes with appropriately dosed and monitored treatment.
Adult Growth Hormone Deficiency (Approved Indication)
Clinical trials in adults with confirmed GH deficiency (often due to pituitary disease, surgery or radiotherapy) have examined body composition, bone density, lipid profile, exercise capacity and quality-of-life outcomes with somatropin replacement, generally reporting improvements in lean mass, reductions in fat mass, and improved quality-of-life measures compared to placebo.
Anti-Ageing and Cosmetic Use (Off-Label — Not an Approved Indication)
A body of research, including the widely cited Rudman et al. 1990 study, has examined GH administration in healthy or age-related GH-declining older adults, reporting changes in body composition (increased lean mass, decreased fat mass) and skin thickness. However, this research does not constitute regulatory approval for anti-ageing use, and subsequent reviews and regulatory bodies have consistently emphasised that GH is not approved for this purpose in any jurisdiction, citing an unfavourable risk-benefit ratio in individuals without a diagnosed GH deficiency.
Bodybuilding and Athletic Performance Use (Off-Label — Not an Approved Indication, Prohibited in Competitive Sport)
GH is used off-label in bodybuilding and performance-enhancement contexts for its anabolic and body-composition effects. This use is not supported by controlled trials in healthy, non-deficient athletic populations of the scale seen for approved indications, is not an approved use anywhere, and GH is prohibited by the World Anti-Doping Agency (WADA) in competitive sport.
Research Data Summary
| Study / Model |
Reported Effect |
| Paediatric GHD RCTs (multiple, decades of data) |
Consistent, well-documented improvement in height velocity and near-adult height outcomes with appropriately monitored somatropin therapy versus untreated GHD. |
| Adult GHD replacement RCTs |
Improved lean body mass, reduced fat mass, improved bone mineral density and quality-of-life scores versus placebo in confirmed AGHD populations. |
| Rudman DR et al. 1990 (healthy older men study) |
Reported increased lean body mass and decreased adipose tissue mass, and increased skin thickness, in men aged 61-81 with low baseline IGF-1; frequently cited (and frequently over-extrapolated) in anti-ageing marketing contexts. |
| Turner syndrome growth trials |
Demonstrated improved final adult height outcomes with somatropin treatment versus untreated historical controls. |
| Athletic performance RCTs in healthy, non-GHD adults |
Evidence for meaningful athletic performance enhancement in healthy, non-deficient adults is notably weaker and more mixed than body-composition findings; several systematic reviews report limited effect on strength/power output despite body-composition changes. |
Stack Combinations Studied
- Somatropin + Insulin (clinical, monitored context) → Research rationale: In some clinical and research settings, insulin co-administration has been studied to counteract GH's mildly diabetogenic/insulin-antagonist effect; this is a medically supervised context, not a general recommendation.
- HGH + IGF-1 or IGF-1 LR3 (off-label, unstudied combination) → Research rationale claimed anecdotally: theorised complementary anabolic signalling via GH-driven endogenous IGF-1 production plus direct exogenous IGF-1 analogue administration; this specific combination has not been studied in controlled trials.
- HGH + Growth hormone secretagogues (e.g., Ipamorelin, CJC-1295) → Not typically combined in research, since secretagogues work by stimulating the pituitary to release endogenous GH — combining with exogenous GH is generally considered redundant from a mechanistic standpoint and is not supported by comparative research.
⚠️ Stack combinations listed for research reference only. Not safety or efficacy guidance. Combinations involving off-label use are not supported by controlled research.
Research Protocol Reference
experimental research protocols only — not dosing recommendations. Approved clinical dosing for diagnosed conditions is individualised by a treating endocrinologist based on weight, indication and IGF-1 monitoring, and is not represented by the generic ranges below.
| Protocol |
Dose (research/clinical literature context only) |
Duration (context only) |
Frequency (context only) |
Research Context |
| Paediatric GHD Clinical Protocol (approved indication, physician-supervised) |
Individualised, typically weight-based (e.g., mcg/kg/day ranges per product literature) |
Years, until growth plates close or target height reached |
Daily subcutaneous injection, typically evening |
Growth hormone deficiency, Turner syndrome and related approved paediatric indications. |
| Adult GHD Clinical Protocol (approved indication, physician-supervised) |
Individualised, low starting dose titrated to IGF-1 levels per product literature |
Long-term, with periodic monitoring |
Daily subcutaneous injection |
Adult growth hormone deficiency replacement. |
| Off-label anti-ageing/performance use (not an approved indication) |
Not an approved or peer-reviewed-consensus dosing protocol; figures circulating in non-clinical sources are not independently verified |
Not established in controlled research for this use case |
Not established in controlled research for this use case |
Not a supported research or clinical protocol; included here only to note that no legitimate dosing standard exists for this use. |
Observed Side Effects in Research
- Fluid retention / peripheral oedema
- Joint pain and myalgia (arthralgia)
- Carpal tunnel syndrome (dose-related, more common in adult replacement therapy)
- Reduced insulin sensitivity / increased blood glucose (diabetogenic effect)
- Headache and, rarely, benign intracranial hypertension (particularly reported in paediatric use)
- Theoretical concern regarding growth-promoting/mitogenic signalling and malignancy risk in long-term use, an area of ongoing pharmacovigilance and epidemiological monitoring (e.g., SAGhE study data)
- Acromegaly-like changes (soft tissue and bone overgrowth) with chronic supraphysiological dosing, as seen in off-label misuse contexts
The side-effect profile is comparatively well characterised for approved, appropriately dosed and monitored clinical use. Off-label use at supraphysiological doses outside medical supervision carries materially different and less well-quantified risks, particularly around glucose metabolism, cardiac structure and long-term proliferative signalling.
Compound Data
- CAS Number
- 12629-01-5
- Molecular Formula
- C990H1528N262O300S7
- Molecular Weight
- Approximately 22,124 Da (191 amino acids)
- Half-Life
- Approximately 15-50 minutes (subcutaneous injection, elimination half-life; varies by product formulation and route)
- Synonyms
- Somatropin, rhGH, recombinant human growth hormone, HGH
- Research Classification
- Recombinant polypeptide hormone; approved medicine (EMA/HPRA) for specific indications; anti-ageing/bodybuilding use is off-label and not an approved indication in any jurisdiction
Scientific References
- [Rudman D et al. 1990] — Effects of human growth hormone in men over 60 years old. — New England Journal of Medicine — [Human RCT]
- [GH Research Society 2007] — Critical evaluation of the safety of recombinant human growth hormone administration: statement from the Growth Hormone Research Society. — Journal of Clinical Endocrinology & Metabolism — [Consensus statement / Review]
- [Carel JC et al. 2012] — Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study. — Journal of Clinical Endocrinology & Metabolism — [Human, epidemiological/observational]
- [Molitch ME et al. 2011] — Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. — Journal of Clinical Endocrinology & Metabolism — [Clinical guideline]
- [Liu H et al. 2008] — Systematic review: the effects of growth hormone on athletic performance. — Annals of Internal Medicine — [Systematic review, human]
- [Baxter RC 1988] — The insulin-like growth factors and their binding proteins. — Comparative Biochemistry and Physiology — [Review, mechanistic background]
*This compliance check is automated and does not constitute legal advice. No Nonsense Fitness recommends independent legal review for all published content.*